The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Seattle Gummy Company’s breakthrough gummy drug program, which delivers Active Pharmaceutical Ingredients (APIs) in its innovative gummy matrix, recently won its first Investigational New Drug Application (IND) approval from FDA on the company’s allergy gummy medication, designated as IND 140312.

Drugs 52

Drugs Allergies Cardiology Drug Delivery 52

Velocity Clinical Research

JANUARY 3, 2024

In my new role as Vice President Corporate Development (CEE) and Medical Director (CEE) together with my expertise of building out a site network, I intend to support the development of Velocity in Poland and in Europe more widely.” About Marek Konieczny, MD, PhD Dr. Konieczny is a specialist in cardiology and internal medicine.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

pharmaphorum

MARCH 15, 2022

Major societies such as the European Society of cardiology (ESC) reported a 177% increase in attendees for its 2020 annual congress : 77,350 virtual attendees (logged-on) 2020 cf 27,946 physical attendees 2019. One important caveat here is that delegate registration fees were waived. Email: lenstarnes@gmail.com. Twitter: @lenstarnes.

Doctors 104

Doctors Doctor Cardiology Allergies 104

Scienmag

JULY 16, 2021

A scientific review has found evidence that a disruption in blood clotting and the first line immune system could be contributing factors in the development of psychosis.

Medicine 73

Medicine Development Research Allergies 73

The Pharma Data

NOVEMBER 4, 2020

Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Research and development (R&D) expense for the three and nine months ended September 30, 2020 were $10.2

Sales 40

Sales Production Cardiology Marketing 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98